Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Reviewed By Analysts

Its quick ratio for most recent quarter is 6.30 along with current ratio for most recent quarter of 6.30.

The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt reduction. Canada Pension Plan Investment Board increased its position in Agios Pharmaceuticals by 31.8% in the third quarter. (AGIO). These ratios are important while doing valuation of the company or the shares of the company. (NASDAQ:AGIO). Free cash flow represents the amount of cash that a company has generated for shareholders after paying off expenses and investing in growth. (AGIO) reported its EPS in the last quarter as $-1.34/Share beating the analyst estimate of $-1.51/Share by the difference of $0.17. TIAA CREF Investment Management LLC now owns 84,412 shares of the biopharmaceutical company's stock worth $4,459,000 after buying an additional 3,636 shares in the last quarter. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

08/08/2016 - Agios Pharmaceuticals, Inc. had its " rating reiterated by analysts at Goldman Sachs. On Tuesday, February 21 NELSEN ROBERT sold $6.68 million worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) or 135,364 shares.

Agios Pharmaceuticals (NASDAQ:AGIO) has insider ownership of 10.55% and institutional ownership of 88.79%. The firm's market cap is $2.13 billion. Agios Pharmaceuticals has recorded a 50-day average of $53.56 and a two hundred day average of $50.53.

According to sentiments of 9 analysts the mean estimates of short term price target for the company's stock is marked at $62.89. This showed the surprise of 13.6% in the last quarter earnings. They expect $-1.83 EPS, down 200.00% or $1.22 from last year's $-0.61 per share. The company's year to date (YTD) performance is at 20.68%. The stock has earnings growth of -24.30% yoy and showed a high EPS growth of 10.60% over the past five years. Analysts forecast that Agios Pharmaceuticals Inc will post ($7.31) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and global copyright laws.

08/19/2016 - BTIG Research began new coverage on Agios Pharmaceuticals, Inc. giving the company a "neutral" rating. The stock has "Buy" rating by SunTrust on Wednesday, March 30. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has a Return on Assets (ROA) of -35.40%.

Investors may be interested in viewing the Gross Margin score on shares of Agios Pharmaceuticals, Inc. They now have a Dollars 75 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of "Buy" and a consensus target price of $63.54. The shares were sold at an average price of $55.00, for a total value of $354,090.00. Insiders now own 0.50% of total outstanding shares. About 758,153 shares traded or 77.09% up from the average. The number of shares now owned by investors are 42.23 mln. The disclosure for this sale can be found here.

The company declined -3.22% and closed its last trading session at $50.36.

Agios Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Recommended News

  • Naked mole-rats can survive near-suffocation

    Naked mole-rats can survive near-suffocation

    North American freshwater turtles and goldfish, for example, spend their winters in oxygen-lacking, ice-covered lakes and ponds. With all those rodents breathing and clogging up burrows, they often encounter low-oxygen and high-carbon dioxide conditions.

    North Korean propaganda video threatens U.S. with missiles

    Next week, US Secretary of State Rex Tillerson will chair a minister-level meeting on the North Korean issue at the UN. We've said it as clearly as we can possibly say it.

    US House panel to hold hearing on consumer airline issues

    No witnesses or precise date was announced, but the hearing comes after a drumbeat of concern from members of Congress. Munoz said that the response to a letter that the CEO sent to a group of United's "most loyal customers" was positive.
  • Oracle to buy digital-ad analytics firm Moat

    Oracle to buy digital-ad analytics firm Moat

    Oracle said it will continue to invest in Moat and to include more functionality and capabilities, brought to market at a quicker pace.

    Dortmund blame bus delay for a torrid night in Monaco

    In another parallel, midfield great Zinedine Zidane was playing for Real Madrid back then and he is now the club's coach. A goal-filled Ligue 1 campaign has them on top their too while they are in the semi-finals of the French Cup as well.

    A new high: Poll finds record support for pot legalization

    The nation's most populous state simply decided it would stop prosecuting sick people for using pot. Generally speaking, though, global marijuana prohibitions are thawing just as they are in the U.S.
  • Mike Pence warns North Korea: 'The sword stands ready'

    That kind of rhetoric has unnerved allies in Japan and South Korea, who would be at the sharp end of any North Korean response. The North has said such launches are an act of deterrence against a potential invasion by the United States or South Korea.
    Jewar airport proposal back on drawing board

    Jewar airport proposal back on drawing board

    So we are doing that technical evaluation", Minister of State for Civil Aviation Jayant Sinha said at a press meet here. By the end of 2017, the airside capacity is expected to rise by 10% to 72-73 aircraft movements per hour.
    Judge blocks Arkansas from using execution drug

    Judge blocks Arkansas from using execution drug

    The ruling came moments after the Arkansas Supreme Court granted a stay to one of two men scheduled for execution Thursday night. Under that timeline, the state would be unable to execute Ward and Davis before its supply of midazolam expires April 30.
  • Jeremy Corbyn says election is not a 'foregone conclusion'

    Jeremy Corbyn says election is not a 'foregone conclusion'

    In her first campaign visit, to a Labour marginal in Bolton, the Prime Minister told an invited audience: "There's a very clear choice at this election".
    Colorado gets new drive-thru pot shop

    Colorado gets new drive-thru pot shop

    The Tumbleweed Express Drive-Thru will be open 4 p.m.to midnight Thursday through Sunday. Parachute is home to about 1,100 people and marijuana is big business in the small town.
    'Infowars' host Jones says his on-air persona not a 'trick'

    'Infowars' host Jones says his on-air persona not a 'trick'

    Jones said he sometimes smokes marijuana - almost yearly - "to monitor its strength, which is how law enforcement does it". Newman questioned Jones on whether he had sex with another woman after his new wife, Erika, had moved in.

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.